论文部分内容阅读
糖尿病肾病是糖尿病常见而又难治的慢性并发症。其治疗的关键在于早期发现,Mogensen认为微量白蛋白尿(尿白蛋白排泄率为20～200μg·min~(-1)或30～300mg/24hr)有预测糖尿病患者出现临床蛋白尿的作用,微量白蛋白阶段称为早期或稳性期糖尿病肾病。在此阶段若严格治疗可防止或延缓糖尿病肾病的发生,国外不少研究证明血管紧张素转换酶抑制剂可降低糖尿病肾病的尿白蛋白排泄率,保护肾功能,延缓甚至阻止向临床期进展,而且可明显减缓临床期糖尿病肾病的肾功能恶化。依那普利(Enalapril)是第二代血管紧张素转换酶的抑制剂,本实验以其对早期及临床期糖尿病肾病进行治疗,观察其对肾血流动力学及其尿白蛋白的影响。
Diabetic nephropathy is a common and refractory chronic complication of diabetes. The key to the treatment is early detection. According to Mogensen, microalbuminuria (urinary albumin excretion rate of 20 ~ 200μg · min -1 or 30 ~ 300mg / 24hr) has been suggested to predict clinical proteinuria in diabetic patients. The albumin stage is called early stage or stable stage diabetic nephropathy. If strict treatment during this stage can prevent or delay the occurrence of diabetic nephropathy, many foreign studies have shown that angiotensin-converting enzyme inhibitors can reduce the urinary albumin excretion rate of diabetic nephropathy, protect renal function, delay or even prevent the progress to the clinical stage, But also significantly slowed the deterioration of renal function in clinical diabetic nephropathy. Enalapril is an inhibitor of second generation angiotensin converting enzyme. In this experiment, we used it to treat early stage and clinical stage diabetic nephropathy, and observed its effect on renal hemodynamics and urinary albumin.